Indonesia Launches Southeast Asia’s First Plasma-Derived Therapy Ecosystem

RRI.CO.ID, Jakarta – Indonesia is taking an important step toward strengthening national health resilience by partnering with global biopharmaceutical company Takeda to establish a plasma-derived therapies (PODP) ecosystem. The initiative, backed by an initial investment of up to USD 30 million, marks the first program of its kind in Southeast Asia and aims to expand public access to plasma-based treatments.

Indonesian Health Minister Budi Gunadi Sadikin said the collaboration reflects the government’s commitment to building strategic health industries and ensuring wider access to innovative therapies. “Through this partnership with Takeda, we hope to reinforce the national health system while preparing Indonesia for future health challenges,” he said, as quoted by Antara.

Under the agreement, Takeda has been designated to conduct plasma fractionation, enabling the gradual development of plasma collection and processing facilities as part of a national plasma industry ecosystem. The plan includes establishing plasma banks across Indonesia within two years, all operating under international quality standards and leveraging Takeda’s global expertise.

The initiative is expected to boost domestic availability of plasma-derived medicines, create new jobs for healthcare professionals and laboratory technicians, and enhance human resource capacity through training and knowledge transfer. Takeda also signaled interest in exploring advanced manufacturing facilities in Indonesia to serve both domestic and global markets.

President of Takeda’s Plasma-Derived Therapies unit, Ramy Riad, said the company is proud to expand its cooperation with Indonesia. “We hope our global experience can support Indonesia’s long-term goals in improving healthcare services, creating high-skilled jobs, and strengthening access to life-saving therapies,” he said.

The partnership involves the Indonesian Ministry of Investment/Investment Coordinating Board (BKPM) and the Coordinating Ministry for Economic Affairs, underscoring its strategic importance.

Investment Minister Rosan P. Roeslani emphasized that beyond capital, the project brings technology transfer, workforce development, and new employment opportunities. “This is a strategic investment that not only strengthens Indonesia’s health ecosystem but also supports our vision of becoming a regional hub for health innovation and advanced pharmaceutical manufacturing,” he said.

The first plasma bank is targeted to begin operations in 2027 as part of Takeda’s BioLife network. While Indonesia’s plasma fractionation facility remains under review, collected plasma will be processed through Takeda’s global manufacturing system, with priority given to meeting domestic needs in line with prevailing national regulations. ***